NasdaqGS:CAPRBiotechs
Capricor Therapeutics (CAPR) Posts US$50 Million H1 Loss Reinforcing Bearish Cash Burn Narrative
Capricor Therapeutics (CAPR) has just posted its FY 2025 first half results with total revenue of US$0 million and a basic EPS loss of US$1.10, while trailing twelve month revenue sits at US$13.39 million with a basic EPS loss of US$1.66. Over recent periods, the company has reported revenue of US$8.88 million and US$13.39 million across the two halves of FY 2024, alongside basic EPS losses of US$0.66 and US$0.51. This provides context for how current margins remain under pressure. With...